PL1845966T3 - Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych - Google Patents
Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowychInfo
- Publication number
- PL1845966T3 PL1845966T3 PL06700207T PL06700207T PL1845966T3 PL 1845966 T3 PL1845966 T3 PL 1845966T3 PL 06700207 T PL06700207 T PL 06700207T PL 06700207 T PL06700207 T PL 06700207T PL 1845966 T3 PL1845966 T3 PL 1845966T3
- Authority
- PL
- Poland
- Prior art keywords
- prophylaxis
- treatment
- glutamine
- pharmaceutical preparation
- alpha
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 abstract 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 229930195712 glutamate Natural products 0.000 abstract 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 2
- 229960003104 ornithine Drugs 0.000 abstract 2
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL372183A PL372183A1 (pl) | 2005-01-11 | 2005-01-11 | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
| EP06700207A EP1845966B1 (en) | 2005-01-11 | 2006-01-10 | Pharmaceutical preparation for use in the treatment or prophylaxis of neoplastic diseases |
| PCT/PL2006/000003 WO2006075924A1 (en) | 2005-01-11 | 2006-01-10 | Antineoplastic preparation and the use of antineoplastic preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1845966T3 true PL1845966T3 (pl) | 2011-02-28 |
Family
ID=36168380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL372183A PL372183A1 (pl) | 2005-01-11 | 2005-01-11 | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
| PL06700207T PL1845966T3 (pl) | 2005-01-11 | 2006-01-10 | Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL372183A PL372183A1 (pl) | 2005-01-11 | 2005-01-11 | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7759396B2 (pl) |
| EP (1) | EP1845966B1 (pl) |
| JP (2) | JP2008526838A (pl) |
| CN (1) | CN101111241B (pl) |
| AT (1) | ATE474570T1 (pl) |
| AU (1) | AU2006205279B2 (pl) |
| CA (1) | CA2593780C (pl) |
| DE (1) | DE602006015608D1 (pl) |
| DK (1) | DK1845966T3 (pl) |
| ES (1) | ES2349233T3 (pl) |
| PL (2) | PL372183A1 (pl) |
| WO (1) | WO2006075924A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2033623A1 (en) * | 2007-09-07 | 2009-03-11 | Cutech S.R.L. | Compositions comprising ornithine ketoglutarate (OKG) |
| WO2015123229A1 (en) * | 2014-02-12 | 2015-08-20 | The Regents Of The University Of California | Compositions and methods for treating aging and age-related diseases and symptoms |
| WO2025263592A1 (ja) * | 2024-06-19 | 2025-12-26 | Ａｇｃ株式会社 | グルタミン代謝阻害剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT393221B (de) * | 1988-02-03 | 1991-09-10 | Leopold Pharma Gmbh | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken |
| FR2775901B1 (fr) * | 1998-03-13 | 2000-07-21 | Logeais Labor Jacques | Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments |
| SE0201713D0 (sv) * | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
| CN1802152A (zh) | 2002-08-01 | 2006-07-12 | 艾斯根公司 | 用谷氨酰胺改善癌症的治疗 |
| AT412447B (de) * | 2002-11-27 | 2005-03-25 | C Y L Handelsges M B H | Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung |
| ES2275218T3 (es) * | 2003-05-07 | 2007-06-01 | Osteologix A/S | Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos. |
| US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
| AU2005316295B2 (en) * | 2004-12-17 | 2012-03-22 | Alan B. Cash | Method for extending lifespan and delaying the onset of age-related disease |
-
2005
- 2005-01-11 PL PL372183A patent/PL372183A1/pl not_active Application Discontinuation
-
2006
- 2006-01-10 PL PL06700207T patent/PL1845966T3/pl unknown
- 2006-01-10 DE DE602006015608T patent/DE602006015608D1/de not_active Expired - Lifetime
- 2006-01-10 AU AU2006205279A patent/AU2006205279B2/en not_active Ceased
- 2006-01-10 DK DK06700207.1T patent/DK1845966T3/da active
- 2006-01-10 CA CA2593780A patent/CA2593780C/en not_active Expired - Fee Related
- 2006-01-10 JP JP2007550321A patent/JP2008526838A/ja not_active Ceased
- 2006-01-10 CN CN2006800019675A patent/CN101111241B/zh not_active Expired - Fee Related
- 2006-01-10 US US11/813,526 patent/US7759396B2/en not_active Expired - Fee Related
- 2006-01-10 EP EP06700207A patent/EP1845966B1/en not_active Expired - Lifetime
- 2006-01-10 ES ES06700207T patent/ES2349233T3/es not_active Expired - Lifetime
- 2006-01-10 WO PCT/PL2006/000003 patent/WO2006075924A1/en not_active Ceased
- 2006-01-10 AT AT06700207T patent/ATE474570T1/de not_active IP Right Cessation
-
2012
- 2012-10-01 JP JP2012219701A patent/JP2013035864A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101111241A (zh) | 2008-01-23 |
| JP2008526838A (ja) | 2008-07-24 |
| US20080058422A1 (en) | 2008-03-06 |
| WO2006075924A1 (en) | 2006-07-20 |
| ATE474570T1 (de) | 2010-08-15 |
| PL372183A1 (pl) | 2006-07-24 |
| CN101111241B (zh) | 2010-12-01 |
| AU2006205279B2 (en) | 2011-05-26 |
| AU2006205279A1 (en) | 2006-07-20 |
| DK1845966T3 (da) | 2010-11-08 |
| EP1845966A1 (en) | 2007-10-24 |
| DE602006015608D1 (de) | 2010-09-02 |
| CA2593780C (en) | 2013-11-26 |
| EP1845966B1 (en) | 2010-07-21 |
| ES2349233T3 (es) | 2010-12-29 |
| CA2593780A1 (en) | 2006-07-20 |
| US7759396B2 (en) | 2010-07-20 |
| JP2013035864A (ja) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07452A1 (en) | Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine | |
| MX341883B (es) | Composicion farmaceutica para el tratamiento y prevencion de canceres. | |
| ZA200707508B (en) | 2-[isoquinolin-3-carbonyl) amino] -propionic acid derivatives as inhibitors of factors XI and IX for the treatment of thrombosis | |
| TW200634051A (en) | Processes for preparing a polypeptide | |
| WO2011107653A3 (en) | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | |
| EP2584043A3 (en) | Anti-glypican 3 antibody having improved kinetics in plasma | |
| AU2008267058A8 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| IL185031A0 (en) | Method for the preparation of pregabalin and salts thereof | |
| WO2006128058A3 (en) | Thyromimetics for the treatment of fatty liver diseases | |
| WO2008053297A3 (en) | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa | |
| MX2008014273A (es) | Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion. | |
| MXPA05014082A (es) | Acidos biariloximetilarenocarboxilicos. | |
| WO2008021463A3 (en) | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | |
| WO2006062424A3 (en) | Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system | |
| WO2007053390A3 (en) | Methods for the use of branched chain amino acids | |
| TNSN07228A1 (en) | Manufacture process of organic compounds | |
| WO2007000001A3 (en) | Pleuromutilin salts with salicylic acid, azelaic acid, sebacic acid and diclofenac | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| DK1845966T3 (da) | Farmaceutisk sammensætning til anvendelse i behandlingen eller forebyggelsen af neoplastiske sygdomme | |
| TW200612922A (en) | Inhibitors of hsp90 | |
| UA94042C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
| MXPA05006408A (es) | Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos. | |
| UA83900C2 (en) | Amorphous forms of risedronate monosodium | |
| MX2022001076A (es) | Metodo para tratar la enfermedad de alzheimer mediante la inhibicion de la captacion de aminoacidos por las celulas t. | |
| EP1806983B8 (en) | Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal |